Skip to main content
Retour
Watch Compare

Inhibitor Therapeutics, Inc.

Qualité des données : 83%
INTI
OTC Manufacturing Chemicals
0,10 €
▲ 0,02 € (25,00%)
Cap. Boursière: 17,26 M
Prix
0,10 €
Cap. Boursière
17,26 M
Fourchette du Jour
0,08 € — 0,08 €
Fourchette 52 Semaines
0,03 € — 0,12 €
Volume
30 001
Ouverture 0,08 €
Moyenne 50J / 200J
0,08 €
20,63% above
Moyenne 50J / 200J
0,06 €
72,41% above

Quick Summary

Points Clés

Negative free cash flow of -3,23 M

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-917,92%
En dessous de la moyenne du secteur (-53,41%)
ROIC-79,44%
Net MarginN/A
Op. MarginN/A

Sécurité

Debt / Equity
N/A
Current Ratio35,00
Interest CoverageN/A

Valorisation

PE (TTM)
-5,23
En dessous de la moyenne du secteur (-1,48)
P/B Ratio4997,79
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1364 pairs)
Métrique Action Médiane du Secteur
P/E -5,2 -1,5
P/B 4997,8 1,6
ROE % -917,9 -53,4
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -3,30 M
ROE -917,92% ROA -93,72%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -3,23 M
ROIC -79,44% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 35,00
Interest Coverage N/A Asset Turnover N/A
Working Capital 2,98 M Tangible Book Value 3 453
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -5,23 Forward P/E N/A
P/B Ratio 4997,79 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -18,72%
Market Cap 17,26 M Enterprise Value 14,28 M
Per Share
EPS (Diluted TTM) -0,02 Revenue / Share N/A
FCF / Share -0,02 OCF / Share -0,02
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 97,91%
SBC-Adj. FCF -3,25 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — 0,0
Net Income -3,30 M -3,34 M -3,03 M 12,11 M -298 632,0
EPS (Diluted) -0,02 -0,02 -0,02 0,03 —
Gross Profit — — — — —
Operating Income -3,43 M -3,66 M -3,40 M -657 926,0 -325 395,0
EBITDA — — — — —
R&D Expenses 1,70 M 1,68 M 1,38 M 6 150,0 4 905,0
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense — — 23 234,0 23 234,0 -14 837,0
Income Tax — — 55 109,0 55 109,0 0,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 2,51 M 5,69 M 8,95 M 11,98 M 58 784,0
Total Liabilities 3,80 M 3,71 M 3,67 M 3,68 M 3,68 M
Shareholders' Equity -1,29 M 1,99 M 5,28 M 8,30 M -3,62 M
Total Debt — — — — —
Cash & Equivalents 2,38 M 5,61 M 8,84 M 11,95 M 30 626,0
Current Assets 2,45 M 5,69 M 8,95 M 11,98 M 58 784,0
Current Liabilities 766 330,0 709 618,0 665 164,0 678 782,0 679 630,0